Skip to main content

Patient-Derived Models of Cancer Program

The Patient-Derived Models of Cancer (PDMC) program is developing and characterizing patient-derived models to define the biological mechanisms that drive cancer phenotype and response to perturbations. The program is testing and comparing distinct patient-derived models developed from common patient samples with the objective of improving the understanding of the strengths and limitations of different patient-derived models as representatives of human tumors. Additionally, the program is undertaking systematic studies of patient-derived model parameters related to intrinsic tumor factors and microenvironmental pressures to explore fundamental cancer biology research questions. The goal of the PDMC is to improve patient-derived models for cancer biology research that may inform the development of novel cancer therapies. 

The PDMC program consists of specialized U01 research projects. The multidisciplinary teams of these projects include researchers with expertise in sample procurement, patient-derived models, cancer biology, computational science and other disciplines. Additionally, the PDMC has a unique framework for sharing data and best practices to accelerate and standardize efforts related to the use of patient-derived models across the cancer research community.

Some PDMC researchers are generating and credentialing patient-derived xenograft (PDX) models. Additional information about PDX models and the PDX models Minimal Information standard (PDX-MI) is available at PDXFinder (an NCI-supported resource for the cancer research community).

The PDMC was funded through PAR-16-344: Biological Comparisons in Patient-Derived Models of Cancer. Monthly steering committee meetings are co-chaired by Drs. Rosalie Sears and Anita Hjelmeland. 

Funded Projects (as of April 2021)
Institution MPI Contact Project Title
Cold Spring Harbor Laboratory – Jackson Laboratory Dr. David Tuveson CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity
Duke University Dr. Xiling Shen Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer
Lurie Children's Hospital of Chicago Dr. Xiao-Nan Li Matching Panels of in vivo and in vitro Model System of Pediatric Brain Tumors
Oregon Health & Science University Dr. Rosalie C. Sears  Comparative Analysis between Patient-derived Models of Pancreatic Ductal Adenocarcinomas and Matched Tumor Specimens
University of Alabama at Birmingham Dr. Christopher D. Willey Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress
University of California, San Francisco Dr. John Kurhanewicz Metabolic Imaging Comparisons of Patient-Derived Models of Renal Cell Carcinoma
University of Texas MD Anderson Cancer Center Dr. Nora Navone Patient-Derived Models of Prostate Cancer for Personalized Medicine
University of Texas Southwestern Medical Center Dr. Sean Morrison The Metabolic Regulation of Melanoma Metastasis
University of Utah Dr. Bryan E. Welm Longitudinal Models of Breast Cancer for Studying Mechanisms of Therapy Response and Resistance
Yale University Dr. Katie Politi Uncovering the Biology of Resistance to TKI in EGFR Mutant Lung Cancer